Haemonetics (NYSE:HAE) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Haemonetics (NYSE:HAE) from a hold rating to a buy rating in a research report report published on Monday.

A number of other equities analysts have also weighed in on HAE. Needham & Company LLC lowered their target price on Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Raymond James reaffirmed a “strong-buy” rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Barrington Research lowered their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and cut their price target for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Finally, JMP Securities lowered their price objective on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Price Performance

Haemonetics stock opened at $62.59 on Monday. The stock’s 50 day moving average price is $62.69 and its two-hundred day moving average price is $71.59. The stock has a market capitalization of $3.14 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 1.11 and a beta of 0.41. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. Haemonetics has a 52-week low of $55.30 and a 52-week high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. On average, equities analysts predict that Haemonetics will post 4.55 earnings per share for the current year.

Institutional Trading of Haemonetics

A number of large investors have recently added to or reduced their stakes in HAE. TD Waterhouse Canada Inc. bought a new position in shares of Haemonetics during the 4th quarter valued at approximately $25,000. Covestor Ltd lifted its stake in Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 439 shares during the last quarter. Whittier Trust Co. bought a new position in Haemonetics during the fourth quarter valued at $62,000. Parkside Financial Bank & Trust increased its position in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 240 shares during the last quarter. Finally, AlphaQuest LLC raised its stake in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after buying an additional 1,826 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.